Nonetheless, approximately 10–15% of GIST cases lack mutations in these genes and are classified as “wild-type GISTs.” These tumors typically do not respond to imatinib, the standard treatment for GISTs with KIT or PDGFRα mutations (Nishida et al., 2024). Here, KIT is linked to gastrointestinal stromal tumor.